BMS-1001

CAS No. 2113650-03-4

BMS-1001( BMS 1001 | BMS1001 )

Catalog No. M13359 CAS No. 2113650-03-4

A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 201 Get Quote
10MG 295 Get Quote
25MG 500 Get Quote
50MG 705 Get Quote
100MG 981 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BMS-1001
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
  • Description
    A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BMS 1001 | BMS1001
  • Pathway
    Immunology/Inflammation
  • Target
    PD-1/PD-L1
  • Recptor
    PD-1/PD-L1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2113650-03-4
  • Formula Weight
    631.122
  • Molecular Formula
    C35H35ClN2O7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    (2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-methylbenzyl)-D-serine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Guzik K, et al. J Med Chem. 2017 Jul 13;60(13):5857-5867. 2. Chupak, L.S., and Zheng, X. Compounds useful as immunomodulators. PCT/US2014/053695, (2015).
molnova catalog
related products
  • Tislelizumab

    Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.

  • BMS-202

    BMS-202 is a small molecule inhibitor of the PD-1/PD-L1 interaction with IC50 of 18 nM in a homogenous time-resolved fluorescence binding assay.

  • IMMH 010 maleate

    IMMH 010 maleate (YPD-30 maleate) is an orally available programmed cell death ligand 1 inhibitor with potential antitumor activity for the study of neurological disorders and advanced malignant solid tumors.